Zager, J. S., Orloff, M. M., Ferrucci, P. F., Choi, J., Eschelman, D. J., Glazer, E. S., … Ottensmeier, C. H. H. (2024). Melphalan/hepatic delivery system versus best available care in patients with unresectable metastatic uveal melanoma: Randomized FOCUS trial results. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 42).

Zager, Jonathan S., Marlana M. Orloff, Pier Francesco Ferrucci, Junsung Choi, David J. Eschelman, Evan Scott Glazer, Aslam Ejaz, et al. “Melphalan/hepatic delivery system versus best available care in patients with unresectable metastatic uveal melanoma: Randomized FOCUS trial results.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 42, 2024.

Zager JS, Orloff MM, Ferrucci PF, Choi J, Eschelman DJ, Glazer ES, et al. Melphalan/hepatic delivery system versus best available care in patients with unresectable metastatic uveal melanoma: Randomized FOCUS trial results. In: JOURNAL OF CLINICAL ONCOLOGY. 2024.

Zager, Jonathan S., et al. “Melphalan/hepatic delivery system versus best available care in patients with unresectable metastatic uveal melanoma: Randomized FOCUS trial results.” JOURNAL OF CLINICAL ONCOLOGY, vol. 42, no. 16, 2024.

Zager JS, Orloff MM, Ferrucci PF, Choi J, Eschelman DJ, Glazer ES, Ejaz A, Richtig E, Ochsenreither S, Reddy SA, Lowe MC, Beasley G, Gesierich AH, Gschnell M, Dummer R, Arance AM, Fenwick SW, John J, Wheater M, Ottensmeier CHH. Melphalan/hepatic delivery system versus best available care in patients with unresectable metastatic uveal melanoma: Randomized FOCUS trial results. JOURNAL OF CLINICAL ONCOLOGY. 2024.